Natco Pharma gets USFDA’s EIR for Visakhapatnam plant
SENSEX 83,173.84 + 152.09 NIFTY 25,519.45 + 5.15 CRUDEOIL 7,752.00 -55.00 GOLD 121,857.00 -5,595.00 SILVER 147,112.00 -10,370.00 SENSEX 83,173.84 + 152.09 NIFTY 25,519.45 + 5.15 NIFTY 25,519.45 + 5.15 CRUDEOIL 7,752.00…

+ 152.09
NIFTY 25,519.45+ 5.15
CRUDEOIL 7,752.00-55.00
GOLD 121,857.00-5,595.00
SILVER 147,112.00-10,370.00
SENSEX 83,173.84+ 152.09
NIFTY 25,519.45+ 5.15
NIFTY 25,519.45+ 5.15
CRUDEOIL 7,752.00-55.00
CRUDEOIL 7,752.00-55.00
GOLD 121,857.00-5,595.00
'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.August inspection drew four Form-483 observations; regulator classifies as Voluntary Action Indicated
By BL Hyderabad Bureau
Updated - November 20, 2026 at 10:57 AM. | HyderabadNatco Pharma has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its FDF manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh.
The US regulator conducted the inspection at the plant during August 17-21, 2026. “On conclusion of the inspection, the Company had received four observations in the Form-483. The company has received EIR from the US FDA on the classification of the above-referred inspection as Voluntary Action Indicated (VAI),” Natco Pharma said in a release on Friday.
Published on November 20, 2026
THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!- Access 10 free stories per month
- Get notified by email for early preview to new features, discounts & offers
Figures reflect the source report and its stated period. This article is for information and is not investment advice.



